Free Trial
NASDAQ:COYA

Coya Therapeutics (COYA) Stock Price, News & Analysis

Coya Therapeutics logo
$6.43 +0.09 (+1.42%)
Closing price 08/5/2025 04:00 PM Eastern
Extended Trading
$6.36 -0.07 (-1.17%)
As of 04:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Coya Therapeutics Stock (NASDAQ:COYA)

Key Stats

Today's Range
$6.25
$6.50
50-Day Range
$5.32
$6.72
52-Week Range
$4.65
$10.24
Volume
20,205 shs
Average Volume
84,128 shs
Market Capitalization
$107.57 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.50
Consensus Rating
Buy

Company Overview

Coya Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
39th Percentile Overall Score

COYA MarketRank™: 

Coya Therapeutics scored higher than 39% of companies evaluated by MarketBeat, and ranked 1382nd out of 1,841 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Coya Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Coya Therapeutics has only been the subject of 4 research reports in the past 90 days.

  • Read more about Coya Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Coya Therapeutics are expected to decrease in the coming year, from ($1.15) to ($1.47) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Coya Therapeutics is -6.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Coya Therapeutics is -6.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Coya Therapeutics has a P/B Ratio of 2.71. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Coya Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    1.61% of the float of Coya Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Coya Therapeutics has a short interest ratio ("days to cover") of 4.1.
  • Change versus previous month

    Short interest in Coya Therapeutics has recently decreased by 0.99%, indicating that investor sentiment is improving.
  • Dividend Yield

    Coya Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Coya Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.61% of the float of Coya Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Coya Therapeutics has a short interest ratio ("days to cover") of 4.1.
  • Change versus previous month

    Short interest in Coya Therapeutics has recently decreased by 0.99%, indicating that investor sentiment is improving.
  • News Sentiment

    Coya Therapeutics has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Coya Therapeutics this week, compared to 2 articles on an average week.
  • MarketBeat Follows

    3 people have added Coya Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Coya Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    12.00% of the stock of Coya Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 39.75% of the stock of Coya Therapeutics is held by institutions.

  • Read more about Coya Therapeutics' insider trading history.
Receive COYA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Coya Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

COYA Stock News Headlines

Trump set to Boost Social Security Checks by 400%?
If you're collecting or planning to collect social security... You should see this presentation about President Trump's Executive Order #14196. Legendary investor Louis Navellier believes it could soon not only save Social Security from collapse... But BOOST benefits for millions of retirees by up to 400%. No wonder the financial times called this new initiative...
See More Headlines

COYA Stock Analysis - Frequently Asked Questions

Coya Therapeutics' stock was trading at $5.73 at the beginning of the year. Since then, COYA shares have increased by 12.2% and is now trading at $6.43.

Coya Therapeutics, Inc. (NASDAQ:COYA) issued its quarterly earnings results on Tuesday, May, 13th. The company reported ($0.44) EPS for the quarter, hitting the consensus estimate of ($0.44). The company had revenue of $257.88 million for the quarter, compared to analyst estimates of $2.63 million.

Coya Therapeutics (COYA) raised $15 million in an IPO on Thursday, December 29th 2022. The company issued 3,050,000 shares at $5.00 per share.

Top institutional shareholders of Coya Therapeutics include AIGH Capital Management LLC (6.61%). Insiders that own company stock include David S Snyder, Arun Swaminathan and Fred Grossman.
View institutional ownership trends
.

Shares of COYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Coya Therapeutics investors own include Broadcom (AVGO), NVIDIA (NVDA), Arista Networks (ANET), Disc Medicine (IRON), Jabil (JBL), Adobe (ADBE) and e.l.f. Beauty (ELF).

Company Calendar

Last Earnings
5/13/2025
Today
8/05/2025
Next Earnings (Estimated)
8/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:COYA
CIK
1835022
Fax
N/A
Employees
6
Year Founded
N/A

Price Target and Rating

High Price Target
$18.00
Low Price Target
$14.00
Potential Upside/Downside
+156.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.07)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$14.88 million
Net Margins
N/A
Pretax Margin
-484.56%
Return on Equity
-48.88%
Return on Assets
-43.32%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
8.84
Quick Ratio
8.84

Sales & Book Value

Annual Sales
$3.55 million
Price / Sales
30.30
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.37 per share
Price / Book
2.71

Miscellaneous

Outstanding Shares
16,730,000
Free Float
14,718,000
Market Cap
$107.57 million
Optionable
Not Optionable
Beta
0.26

Social Links

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:COYA) was last updated on 8/6/2025 by MarketBeat.com Staff
From Our Partners